Bayer invests 130 million EUR in new production facility for innovative parenteral products
|
23 November 2023 |
Bayer and Recursion focus research collaboration on oncology
|
10 November 2023 |
Bayer expands global life science incubator network
|
07 November 2023 |
Bayer and Broad Institute of MIT and Harvard extend research collaboration to develop new cancer therapies
|
02 November 2023 |
AskBio contribution to advancing gene therapy highlighted at ESGCT 30th Congress
|
25 October 2023 |
Bayer invests 250 million USD in new cell therapy manufacturing facility in the U.S.
|
11 October 2023 |
Bayer to partner with Twist Bioscience to accelerate drug discovery
|
05 October 2023 |
Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator
|
18 September 2023 |
BlueRock's Phase I study with bemdaneprocel in patients with Parkinson's disease meets primary endpoint
|
30 August 2023 |
Mahana Therapeutics signs agreement with Consumer Health division of Bayer to commercialize digital therapeutics
|
22 August 2023 |
Aflibercept 8 mg first to achieve sustained vision gains with more than 70% of patients extended to intervals between 16 and 24 weeks in wet age-related macular degeneration at two years
|
10 August 2023 |
Bayer extends partnership with Peking University to foster pharmaceutical innovation in China
|
10 July 2023 |
Bayer's new pharmaceutical R&D strategy to accelerate breakthrough innovations
|
28 June 2023 |
Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology
|
13 June 2023 |
Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics
|
07 June 2023 |
Bayer launches unit to develop new precision health consumer products
|
31 May 2023 |
Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program
|
16 May 2023 |
Bayer opens first Co.Lab Life science incubator in Cambridge
|
10 May 2023 |
Bayer Pharmaceuticals accelerates innovations for patients
|
31 March 2023 |
BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
|
21 March 2023 |